These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 11844823

  • 1. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
    Harbeck N, Kates RE, Schmitt M.
    J Clin Oncol; 2002 Feb 15; 20(4):1000-7. PubMed ID: 11844823
    [Abstract] [Full Text] [Related]

  • 2. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
    Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA.
    Cancer Res; 2002 Aug 15; 62(16):4617-22. PubMed ID: 12183417
    [Abstract] [Full Text] [Related]

  • 3. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
    Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, Hasmüller S, Kiechle M, Jänicke F, Thomssen C, Chemo-N 0 Study Group.
    Eur J Cancer; 2013 May 15; 49(8):1825-35. PubMed ID: 23490655
    [Abstract] [Full Text] [Related]

  • 4. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
    Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M, German N0 Study Group.
    J Natl Cancer Inst; 2001 Jun 20; 93(12):913-20. PubMed ID: 11416112
    [Abstract] [Full Text] [Related]

  • 5. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S, Vrhovec I, Svetic B, Cufer T.
    Clin Breast Cancer; 2002 Jun 20; 3(2):138-46. PubMed ID: 12123538
    [Abstract] [Full Text] [Related]

  • 6. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M.
    Cancer Res; 1993 Jun 01; 53(11):2513-21. PubMed ID: 8388317
    [Abstract] [Full Text] [Related]

  • 7. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
    Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C, Yurdseven S, Höfler H, Kiechle M, Schmitt M, Harbeck N.
    J Clin Oncol; 2003 Mar 15; 21(6):1022-8. PubMed ID: 12637466
    [Abstract] [Full Text] [Related]

  • 8. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.
    Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Jänicke F, Thomssen C.
    Clin Breast Cancer; 2002 Aug 15; 3(3):196-200. PubMed ID: 12196277
    [Abstract] [Full Text] [Related]

  • 9. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.
    Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F, Thomassen C, Look MP, Foekens JA.
    Clin Breast Cancer; 2004 Dec 15; 5(5):348-52. PubMed ID: 15585071
    [Abstract] [Full Text] [Related]

  • 10. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.
    Cancer Res; 2000 Feb 01; 60(3):636-43. PubMed ID: 10676647
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant chemotherapy in node-negative breast cancer: UPA/PAI-1 determinations for 163 cases.
    Vénat-Bouvet L, Fermeaux V, Leobon S, Saidi N, Monteil J, Mollard J, Aubard Y, Jammet I, Tubiana-Mathieu N.
    Anticancer Res; 2014 Mar 01; 34(3):1213-7. PubMed ID: 24596362
    [Abstract] [Full Text] [Related]

  • 12. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
    Hundsdorfer B, Zeilhofer HF, Bock KP, Dettmar P, Schmitt M, Kolk A, Pautke C, Horch HH.
    J Craniomaxillofac Surg; 2005 Jun 01; 33(3):191-6. PubMed ID: 15878520
    [Abstract] [Full Text] [Related]

  • 13. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA, Look MP, Peters HA, van Putten WL, Portengen H, Klijn JG.
    J Natl Cancer Inst; 1995 May 17; 87(10):751-6. PubMed ID: 7563153
    [Abstract] [Full Text] [Related]

  • 14. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients.
    de Witte JH, Sweep CG, Klijn JG, Grebenschikov N, Peters HA, Look MP, van Tienoven TH, Heuvel JJ, van Putten WL, Benraad TJ, Foekens JA.
    Br J Cancer; 1999 Mar 17; 79(7-8):1190-8. PubMed ID: 10098758
    [Abstract] [Full Text] [Related]

  • 15. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
    Harbeck N, Kates RE, Gauger K, Willems A, Kiechle M, Magdolen V, Schmitt M.
    Thromb Haemost; 2004 Mar 17; 91(3):450-6. PubMed ID: 14983219
    [Abstract] [Full Text] [Related]

  • 16. Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer.
    Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Foekens JA, Beex LV, Sweep CG.
    Cancer Res; 2004 Jan 15; 64(2):659-64. PubMed ID: 14744782
    [Abstract] [Full Text] [Related]

  • 17. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
    Foekens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Jänicke F, Klijn JG.
    J Clin Oncol; 1994 Aug 15; 12(8):1648-58. PubMed ID: 8040677
    [Abstract] [Full Text] [Related]

  • 18. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.
    Harbeck N, Thomssen C, Berger U, Ulm K, Kates RE, Höfler H, Jänicke F, Graeff H, Schmitt M.
    Breast Cancer Res Treat; 1999 Mar 15; 54(2):147-57. PubMed ID: 10424405
    [Abstract] [Full Text] [Related]

  • 19. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Geurts-Moespot A, van Tienoven DT, Beex LV, Sweep FC.
    Cancer; 2004 Aug 01; 101(3):486-94. PubMed ID: 15274061
    [Abstract] [Full Text] [Related]

  • 20. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.
    Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H.
    Breast Cancer Res Treat; 1993 Aug 01; 24(3):195-208. PubMed ID: 8435475
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.